Useful Articles

Indian Market

Budget ignited the markets. With the best known Finance p

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

ersonnel in the whole of Asia, this did not really come as a surprise. B

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

ut market's reaction was a bit overboard.

Technically, we "finally" hav

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

e a breakout as you can clearly see from the chart below. This is the ve

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

ry first time that we actually broke past the upper trendline. And this

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

happened on a great volume and with a huge surge. Another good thing abo

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

ut this breakout is, the next couple of days(post breakout) we have been

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

getting good support from the same resistance line that now serves as a

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

support line. But again, as you can see, MACD is extremely over-stretch

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

ed and so are the other indicators.

US Market

Markets have been consol

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

idating after breaking the 11K barrier, once again. The good thing about

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

the way things are moving is that we have held onto Both 11K(dow) and 2

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

300(Nasdaq). Though both indices did dip below these levels a few times

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

last week, both sustained the wrath and came back up.

Technically, 11K

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

and 2300 are giving extremely good support. As long as we can hold onto

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

these levels, we still have good reasons to be bullish and going long. I

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

n the meanwhile, we have MACD negative divergence. Last time we had this

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

around early Jan, we dipped for a few more sessions before rallying bac

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

k up. We could have a similar scenario this time too. As you can see fro

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

m the trenlines below, we are pretty much on track, both up and downside

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.usefularticles.org.ua/article/117555/usefularticles-Weekly-Technical-Analysis-Week-Ending-3rd-March-2006.html">Weekly Technical Analysis (Week Ending 3rd March, 2006)</a>

BB link (for phorums):
[url=http://www.usefularticles.org.ua/article/117555/usefularticles-Weekly-Technical-Analysis-Week-Ending-3rd-March-2006.html]Weekly Technical Analysis (Week Ending 3rd March, 2006)[/url]

Marketing for a Service Club such as the Rotary, Kiwanis, Knights of Columbus, Optimists, Elks, Lions Club or other networking club is similar to marketing for a small or medium sized business or even a franchising company in many ways and then in other ways it is not really.

Time saving tips to get your writing moving without delays. Don't worry about writer's block when trying to work on your articles or eboks.

Have you read your credit card statement lately? Do you know what your annual percentage rate is? How about your annual fee? You may be surprised to learn that your current card is not the bargain you once thought it was.

Tags

Links

Useful Articles - Weekly Technical Analysis (Week Ending 3rd March, 2006)

Related Articles: